Top Markets
#1 Islamic Coin Islamic Coin +154.45%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +23.10%
#4 MarsCoin MarsCoin +14.90%
#5 BOOK OF MEME BOOK OF MEME +14.69%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.37%
#7 Nockchain Nockchain +11.14%
#8 Starpower Starpower +9.36%
#9 Venom Venom +9.22%
#10 Lighter Lighter +9.20%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Enzo Biochem, Inc. Enzo Biochem, Inc.

Enzo Biochem, Inc.

ENZ
Rank in Stocks #28168
Enzo Biochem, Inc. is a diversified enterprise that encompasses diagnostics,... Enzo Biochem, Inc. is a diversified enterprise that encompasses diagnostics, clinical laboratory services, and life sciences. The company's core activities involve the entire process of researching, developing, manufacturing, and commercializing diagnostic and scientific investigation products, drawing upon advancements in genetic engineering, biotechnology, and molecular biology. Its operations are organized into three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products division is responsible for creating, producing, and distributing vital tools and reagents tailored for customers in clinical research, pharmaceutical development, and broader bioscience research. Its extensive product catalog features items such as proteins, antibodies, peptides, small molecules, labeling agents, dyes, and various kits. These offerings provide life science researchers with the means for target identification and validation, content analysis, gene expression studies, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also supplies specialized solutions to scientific experts investigating critical health areas, including cancer, cardiovascular ailments, neurological disorders, metabolic conditions (like diabetes and obesity), endocrine imbalances, infectious and autoimmune diseases, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment delivers a comprehensive spectrum of molecular and other clinical laboratory tests and procedures. These are utilized by physicians in routine patient care to help confirm or establish diagnoses, monitor the effectiveness of treatments or medications, and identify previously undiagnosed medical conditions. This division operates a central, full-service clinical laboratory in Farmingdale, New York, complemented by a network of 30 patient service centers across New York and New Jersey. Additionally, it runs dedicated "STAT" or rapid-response laboratories in New York City and Connecticut, alongside a full-service phlebotomy facility and an internal logistics department. The Therapeutics segment is dedicated to pioneering novel treatment approaches within the fields of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem distributes its array of products and services through its dedicated internal sales team and an extensive network of distributors, reaching both domestic and international markets. The company was established in 1976 and has its corporate headquarters situated in New York, New York.
Share Price
$0.5495
Last synced: 2025-05-15
Market Cap
$28.14M
Change (1 day)
4.70%
Change (1 year)
0.00%
Country
US
Trade Enzo Biochem, Inc. (ENZ)

Category

Healthcare
Revenue for Enzo Biochem, Inc. (ENZ)
Revenue in Apr 2025 TTM: $27.48M
According to Enzo Biochem, Inc. latest financial reports the company's current revenue (TTM) is $27.48M. In 2023 the company made a revenue of $31.06M a decrease compared to the revenue in the year 2022 that was $107.07M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Enzo Biochem, Inc. from 2000 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $27.48M -13.89%
2024 $31.91M 2.72%
2023 $31.06M -70.99%
2022 $107.07M -9.05%
2021 $117.73M 54.87%
2020 $76.02M -6.34%
2019 $81.17M -22.48%
2018 $104.71M -2.87%
2017 $107.80M 4.90%
2016 $102.77M 5.30%
2015 $97.60M 1.72%
2014 $95.95M 2.39%
2013 $93.71M -9.10%
2012 $103.08M 1.03%
2011 $102.03M 5.10%
2010 $97.08M 8.38%
2009 $89.57M 15.14%
2008 $77.80M 47.04%
2007 $52.91M 32.85%
2006 $39.83M -8.24%
2005 $43.40M 4.22%
2004 $41.64M -21.08%
2003 $52.77M -2.31%
2002 $54.02M -7.52%
2001 $58.41M 16.75%
2000 $50.03M 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 $46.34B 168,547.86%
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 $25.11B 91,281.26%
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 $2.71B 9,752.87%
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 $4.55B 16,472.24%
US